Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

SAN DIEGO, Feb. 8, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2012.

For the fourth quarter of 2012, the Company reported net income of $9.5 million, or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011. For the year ended December 31, 2012, the Company reported net income of $5.0 million, or $0.08 per fully diluted share, as compared to net income of $37.6 million, or $0.67 per fully diluted share, for 2011. One-time milestone payments of $30.0 million during 2011 were primarily responsible for the change in operating results year over year.

The Company's balance sheet at December 31, 2012 reflected total assets of $196.0 million, including cash, investments and receivables of $188.3 million compared with balances at December 31, 2011 of $138.4 million and $131.7 million, respectively.  During January 2012, the Company completed a public offering of approximately 10.9 million shares of common stock that resulted in net proceeds of approximately $83.0 million.

"During 2012 we continued to perform to financial plan and were successful in moving our VMAT2 tardive dyskinesia program forward, as well as AbbVie advancing the elagolix endometriosis and uterine fibroids programs," said Kevin C. Gorman, President and CEO of Neurocrine Biosciences. "Looking to 2013 we will have two Phase IIb readouts for our VMAT2 program, expect AbbVie to progress elagolix into Phase IIb in uterine fibroids, and we anticipate one additional program entering the clinic, resulting in a very productive year."

Revenues for the fourth quarter of 2012 were $21.9 million, compared to $11.1 million for the same period in 2011. The $10.8 million increase in revenue is primarily due to higher rev
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Minn. (PRWEB) March 06, 2015 ... Scientific Symposia sessions for the grain scientists’ Centennial ... abstracts. , 2015 marks the 100th anniversary ... Centennial Meeting in Minneapolis, Minnesota, U.S.A. on October ... from international researchers who are looking to the ...
(Date:3/6/2015)... , March 6, 2015   Senomyx , ... using proprietary taste science technologies to discover, develop, and ... flavor industries, announced today that John Poyhonen , the ... Rogers , Senior Vice President and Chief Financial Officer, ... currently scheduled for Wednesday, March 11, at 2:00 p.m. ...
(Date:3/6/2015)... PARIS , March 6, 2015 /PRNewswire/ ... im Dezember   2011 von der Assistance ... initiiert., Sie ist eine französische, ... 400   Patienten rekrutiert wurden. Verglichen werden ... entweder mit Yttrium-90 Harz-Mikrosphären oder Sorafenib behandelt ...
(Date:3/5/2015)... Buffalo, New York (PRWEB) March 05, 2015 ... want veterans to be able to get an Advanced ... Time, money, stress, blaming and guessing are all risk ... with assuming the woman is the source of the ... and female. LifeCell Dx has the simplest, least ...
Breaking Biology Technology:AACCI Unveils Scientific Symposia Sessions for Centennial Meeting 2SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3
... interpretation, storage and documentation of photograph files focused on ... June 10 EyeIC, an innovator of eye care ... MatchedFlicker(TM) technology has received FDA 510(k) clearance from the ... is a device-agnostic, software-only solution that uses time series ...
... LAKE, N.J., June 10 Strativa Pharmaceuticals, the proprietary ... Pharmaceutical Companies, Inc. (NYSE: PRX ), today ... has accepted its New Drug Application (NDA) for ondansetron ... of ondansetron ODFS for the prevention of nausea and ...
... YORK, June 10 NeoStem, Inc. (NYSE Amex: ... long-term storage of adult stem cells for future medical need, ... Drew Bernstein, CPA and Managing Partner of Bernstein & Pinchuk ... Committee. , , Mr. Bernstein co-founded Bernstein & Pinchuk ...
Cached Biology Technology:EyeIC Receives FDA 510(k) Clearance for MatchedFlicker(TM) Retinal Aid Detection Technology 2EyeIC Receives FDA 510(k) Clearance for MatchedFlicker(TM) Retinal Aid Detection Technology 3Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA 2Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA 3NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Company's Audit Committee 2NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Company's Audit Committee 3
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/23/2015)... Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT ... introduces a new groundbreaking payment method. Payment accounts may ... may only be accessed if both the speech (the ...
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... Technology Professor Xiaojun Yu, Ph.D., has received an ... from the Wallace H. Coulter Foundation. This award ... scaffolds for bone healing. , Yu, Assistant Professor ... Engineering at Stevens Schaefer School of Engineering and ...
... The American Institute of Biological Sciences (AIBS), in conjunction ... fourth annual symposium on evolution on December 1, 2007, ... symposium, titled Evolution: Applications in Human Health and Populations, ... by the National Association of Biology Teachers. ...
... have brought us the resurgence of American bald ... prized lobster fisheries. So how can modern conservation ... catastrophic loss of Guatemalan forests to the economy-crippling ... this week,s special issue of the Proceedings of ...
Cached Biology News:AIBS to cohost symposium on evolution, disease and human health 2AIBS to cohost symposium on evolution, disease and human health 3AIBS to cohost symposium on evolution, disease and human health 4Why conservation efforts often fail 2
...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Complete kit for all types of yeast two-hybrid ... Choice of two bait ... baits , Triple ... Complete set of ...
Biology Products: